Cancer Profiling Market Size, Share, Trends, Growth Outlook

Cancer Profiling Market is estimated to increase at a Compounded Annual Growth Rate of 12.3% CAGR over the forecast period from 2024 to 2030

The Cancer Profiling Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Technology (Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, Others), By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Others), By Biomarker (Genomic, Protein, Others), By Application (Research Application, Clinical Application).

An Introduction to Cancer Profiling Market in 2024

Cancer profiling refers to the comprehensive analysis of a tumor's molecular characteristics, including genetic mutations, gene expression patterns, and protein alterations, to guide cancer diagnosis, prognosis, and treatment decisions. In 2024, cancer profiling encompasses a range of techniques such as next-generation sequencing, gene expression profiling, and proteomic analysis, which provide insights into the underlying biology and heterogeneity of cancer. By profiling tumors at the molecular level, clinicians can classify cancers into subtypes, identify potential therapeutic targets, and predict patient responses to specific treatments. Cancer profiling also plays a crucial role in precision oncology approaches, which aim to match patients with the most effective therapies based on their individual tumor profiles. With advancements in genomic sequencing technology, bioinformatics algorithms, and targeted therapy development, cancer profiling continues to evolve, offering new insights into cancer biology and driving innovations in personalized cancer care. As the field of oncology shifts toward molecularly guided treatment strategies, cancer profiling holds promise for improving patient outcomes, reducing treatment toxicity, and advancing the fight against cancer.

Market Trend: Integration of Multi-Omics Approaches in Cancer Profiling

One prominent trend in the cancer profiling market is the integration of multi-omics approaches. Traditional cancer profiling methods focused on single omics techniques, such as genomics or proteomics, to characterize tumors and guide treatment decisions. However, there is growing recognition of the complex interplay between genomic alterations, epigenetic modifications, transcriptomic changes, and protein expression patterns in driving cancer development and progression. As a result, researchers and clinicians are increasingly adopting multi-omics strategies, which combine genomic, transcriptomic, proteomic, and metabolomic data, to obtain a comprehensive understanding of the molecular landscape of cancer. The integration of multi-omics approaches in cancer profiling enables the identification of novel biomarkers, therapeutic targets, and predictive signatures, leading to more personalized and effective cancer treatment strategies.

Market Driver: Increasing Demand for Precision Medicine and Targeted Therapies

A significant driver in the cancer profiling market is the increasing demand for precision medicine and targeted therapies. Precision medicine aims to tailor medical treatments to individual patient characteristics, including genetic makeup, molecular profile, and environmental factors, to optimize therapeutic outcomes and minimize adverse effects. Cancer profiling plays a crucial role in precision oncology by providing insights into the molecular drivers of cancer and guiding treatment selection, including targeted therapies, immunotherapies, and combination regimens. With the advent of next-generation sequencing (NGS) technologies and high-throughput omics platforms, there is growing accessibility to comprehensive cancer profiling assays that enable rapid and accurate molecular characterization of tumors. The increasing adoption of precision medicine approaches by healthcare providers and pharmaceutical companies drives the demand for cancer profiling services and molecular diagnostics, creating opportunities for market growth and innovation.

Market Opportunity: Development of Liquid Biopsy Assays for Non-Invasive Cancer Profiling

An emerging opportunity in the cancer profiling market is the development of liquid biopsy assays for non-invasive cancer profiling. Liquid biopsy refers to the analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles, obtained from blood, urine, or other bodily fluids. Liquid biopsy offers several advantages over traditional tissue biopsy, including minimal invasiveness, real-time monitoring of tumor dynamics, and detection of treatment resistance and minimal residual disease. With the growing recognition of the clinical utility of liquid biopsy in cancer diagnosis, prognosis, and treatment monitoring, there is a demand for robust and reliable liquid biopsy assays for comprehensive cancer profiling. The development of high-performance liquid biopsy assays that can accurately detect and quantify tumor-derived biomarkers in peripheral blood presents a significant opportunity for diagnostic companies and research organizations to innovate and commercialize new products for cancer detection, monitoring, and personalized treatment strategies. By leveraging liquid biopsy technologies, stakeholders can address unmet clinical needs in cancer profiling and contribute to advancements in precision oncology and patient care.

Cancer Profiling Market Share Analysis: Next-Generation Sequencing (NGS) in Breast Cancer Profiling is the fastest growing segment over the forecast period to 2030

Among the segments in the Cancer Profiling Market, the Next-Generation Sequencing (NGS) in Breast Cancer Profiling segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for NGS technology in breast cancer research and clinical applications. Next-Generation Sequencing enables high-throughput and comprehensive analysis of the entire breast cancer genome, transcriptome, and epigenome, providing valuable insights into the molecular mechanisms underlying breast cancer development, progression, and treatment response. The increasing complexity and heterogeneity of breast cancer necessitate sophisticated genomic profiling techniques to identify genetic alterations, somatic mutations, and gene expression patterns associated with tumor aggressiveness and therapeutic resistance. Furthermore, NGS facilitates the identification of novel biomarkers and therapeutic targets in breast cancer, paving the way for personalized treatment strategies and precision oncology approaches. The expanding adoption of NGS-based liquid biopsies for non-invasive detection of circulating tumor DNA (ctDNA) and monitoring of treatment response further drives the demand for NGS in breast cancer clinical applications. Additionally, advancements in NGS platforms, bioinformatics tools, and data analysis algorithms enhance the accuracy, sensitivity, and scalability of NGS-based assays, making them indispensable tools in breast cancer research and clinical practice. As healthcare providers and researchers increasingly recognize the value of genomic profiling in guiding treatment decisions and improving patient outcomes in breast cancer, the Next-Generation Sequencing in Breast Cancer Profiling segment is expected to sustain its rapid growth in the Cancer Profiling Market.

Cancer Profiling Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossCaris Life Sciences, F. Hoffmann-La Roche Ltd, Foundation Medicine, Genscript Biotech Corp, Guardant Health Inc, Hologic Inc, HTG Molecular Diagnostics Inc, Illumina Inc, NanoString Technologies Inc, NeoGenomics Inc, Predictive Oncology Inc, QIAGEN N.V., Sysmex Corp, Tempus Labs , Thermo Fisher Scientific Inc

Cancer Profiling Market Segmentation

By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cancer Profiling Market Companies

Caris Life Sciences
F. Hoffmann-La Roche Ltd
Foundation Medicine
Genscript Biotech Corp
Guardant Health Inc
Hologic Inc
HTG Molecular Diagnostics Inc
Illumina Inc
NanoString Technologies Inc
NeoGenomics Inc
Predictive Oncology Inc
QIAGEN N.V.
Sysmex Corp
Tempus Labs
Thermo Fisher Scientific Inc

Reasons to Buy the Cancer Profiling Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cancer Profiling Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cancer Profiling Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cancer Profiling Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cancer Profiling Market Size Outlook, $ Million, 2021 to 2030
3.2 Cancer Profiling Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cancer Profiling Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cancer Profiling Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cancer Profiling Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cancer Profiling Industry
4.2 Key Market Trends in Cancer Profiling Industry
4.3 Potential Opportunities in Cancer Profiling Industry
4.4 Key Challenges in Cancer Profiling Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cancer Profiling Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cancer Profiling Market Outlook by Segments
7.1 Cancer Profiling Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application

8 North America Cancer Profiling Market Analysis and Outlook To 2030
8.1 Introduction to North America Cancer Profiling Markets in 2024
8.2 North America Cancer Profiling Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cancer Profiling Market size Outlook by Segments, 2021-2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application

9 Europe Cancer Profiling Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cancer Profiling Markets in 2024
9.2 Europe Cancer Profiling Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cancer Profiling Market Size Outlook by Segments, 2021-2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application

10 Asia Pacific Cancer Profiling Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cancer Profiling Markets in 2024
10.2 Asia Pacific Cancer Profiling Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cancer Profiling Market size Outlook by Segments, 2021-2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application

11 South America Cancer Profiling Market Analysis and Outlook To 2030
11.1 Introduction to South America Cancer Profiling Markets in 2024
11.2 South America Cancer Profiling Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cancer Profiling Market size Outlook by Segments, 2021-2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application
12 Middle East and Africa Cancer Profiling Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cancer Profiling Markets in 2024
12.2 Middle East and Africa Cancer Profiling Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cancer Profiling Market size Outlook by Segments, 2021-2030
By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Caris Life Sciences
F. Hoffmann-La Roche Ltd
Foundation Medicine
Genscript Biotech Corp
Guardant Health Inc
Hologic Inc
HTG Molecular Diagnostics Inc
Illumina Inc
NanoString Technologies Inc
NeoGenomics Inc
Predictive Oncology Inc
QIAGEN N.V.
Sysmex Corp
Tempus Labs
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Technology
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
By Biomarker
Genomic
Protein
Others
By Application
Research Application
Clinical Application
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)